Currentblue cross blue shield - tennesseePolicy N/A

Urinary Tumor Markers for Bladder Cancer - G2125

Defines coverage and reimbursement policy for urinary tumor marker tests (BTA, NMP22, UroVysion FISH, ImmunoCyt/uCyt and other urinary biomarkers) for diagnosis, screening, and surveillance of bladder cancer, including indications where tests meet or do not meet coverage criteria, and references to FDA approvals and clinical guidelines. This part covers policy description, indications/limitations, terminology, scientific background, analytic/clinical validity, guideline positions, and applicable regulations.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyUrinary Tumor Markers for Bladder Cancer - G2125

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionWhen covered, urinary biomarker tests (BTA, NMP22, UroVysion) are to be used as adjuncts to cytology or cystoscopy (e.g., for atypical/equivocal cytology or monitoring high-risk NMIBC) and not as replacements for cystoscopy.

SourceLink

POLICY UPDATE CHANGES

No material clinical/coverage changes identified in this brief (has_material_change=false).

MEETSAdjunct diagnostic exclusion (atypical cytology)

MEETSSurveillance high-risk NMIBC (adjunct)

NOT COVEREDScreening/hematuria/diagnosis in symptoms

ListedFDA-approved tests referenced

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

CLIALDT regulatory status

Coverage Summary

Scope: This policy defines coverage and reimbursement for urinary tumor marker tests for bladder cancer (including BTA, NMP22, UroVysion FISH, ImmunoCyt/uCyt and other urinary biomarkers) and specifies indications where tests meet or do not meet coverage criteria, references to FDA approvals, guideline positions, and regulatory status. It applies to diagnostic, screening, and surveillance uses and notes laboratory-developed test (LDT) considerations.

Overview: Coverage stance is mixed. Certain urinary biomarkers are covered as adjuncts—for example, BTA, NMP22, and UroVysion FISH meet coverage criteria as adjuncts in the diagnostic exclusion of bladder cancer for patients with atypical or equivocal cytology and as adjuncts in the monitoring of high-risk non‑muscle invasive bladder cancer (NMIBC). Fluorescence immunocytology (ImmunoCyt/uCyt) meets coverage criteria only as an adjunct to cystoscopy or cytology for surveillance. By contrast, these urinary biomarkers do not meet coverage criteria for screening, evaluation of hematuria, diagnosing bladder cancer in symptomatic individuals, or other non‑specified indications. The policy references FDA approvals (e.g., UroVysion, ImmunoCyt, BTA, NMP22) and guideline positions that biomarkers may augment but do not replace cystoscopy.

Coverage outcomes (summary)

Covered — adjunct diagnostic exclusionMEETS COVERAGE as an adjunct for diagnostic exclusion in patients with atypical/equivocal cytology

Covered — adjunct surveillance (high-risk NMIBC)MEETS COVERAGE as an adjunct in monitoring high-risk non‑muscle invasive bladder cancer

Not covered — other indicationsDO NOT MEET COVERAGE for screening, evaluation of hematuria, or diagnosing bladder cancer in symptomatic individuals

Regulatory — LDTsMany tests are offered as laboratory‑developed tests (LDTs); LDTs are regulated under CLIA '88 as high‑complexity tests and are not FDA‑approved/cleared

Referenced FDA‑approved testsFDA‑approved examples: Bard BTA (BTA stat, BTA TRAK), MATRITECH NMP22 (NMP22 Test Kit, NMP22 BladderChek), UroVysion FISH, ImmunoCyt (uCyt+)

Medical Necessity / Coverage Determinations

Coverage determinations

Coverage decisions for urinary biomarkers for bladder cancer are as follows:

ALL of the following

Tests that MEET coverage criteria
- Urinary biomarkers (BTA test, NMP22 test, or UroVysion FISH) MEET COVERAGE CRITERIA as an adjunct in the diagnostic exclusion of bladder cancer for patients who have an atypical or equivocal cytology
- Urinary biomarkers (BTA, NMP22, UroVysion FISH) MEET COVERAGE CRITERIA as an adjunct in the monitoring of high-risk, non-muscle invasive bladder cancer
- Fluorescence immunocytology (ImmunoCyt/uCyt) MEETS COVERAGE CRITERIA as an adjunct to cystoscopy or cytology in the monitoring of persons with bladder cancer
Tests that DO NOT MEET coverage criteria

Coding (Referenced tests)

FDA-approved tests referencedneutralCovered

Bard BTA stat	FDA-approved qualitative BTA stat test indicated as an aid in management in conjunction with cystoscopy
BTA TRAK	FDA-approved quantitative BTA TRAK test indicated as an aid in management in conjunction with cystoscopy
MATRITECH NMP22 Test Kit	FDA-approved quantitative NMP22 enzyme immunoassay
NMP22 BladderChek	FDA-approved qualitative NMP22 test for monitoring bladder cancer patients
UroVysion Bladder Cancer Kit	FDA-approved FISH assay detecting chromosomal alterations (chr 3,7,17 and 9p21 loss)
ImmunoCyt (uCyt+)	FDA-approved qualitative immunofluorescence assay indicated as an aid in management in conjunction with cytology and cystoscopy (surveillance only)

This brief does not include CPT, HCPCS, or ICD‑10 billing codes. Claims should follow the payer's coding guidance; map the listed test names (e.g., BTA, NMP22, UroVysion, ImmunoCyt, proprietary/LDT assays) to local billing codes per your billing department or payer-specific instructions.

Provider Actions & Operational Notes

Documentation Required

Adjunct use only

When covered, urinary biomarker tests (BTA, NMP22, UroVysion) must be used only as adjuncts to cytology or cystoscopy (for example, to adjudicate atypical/equivocal cytology or to monitor high‑risk NMIBC) and are not replacements for cystoscopy.

Denial Risk

Not covered indications

Claims for urinary biomarkers are not covered for screening, evaluation of hematuria, diagnosis in symptomatic individuals, or other non‑specified indications; such claims may be denied.

Screening for bladder cancer
Evaluation of hematuria
Diagnosis in symptomatic individuals
All other indications not specified as covered

Clinical Background & Evidence

Background: Bladder cancer is most commonly diagnosed by cystoscopy with urine cytology; cystoscopy is the gold standard. A range of urinary tumor markers (for example, BTA, NMP22, UroVysion FISH, ImmunoCyt, and multiple novel epigenetic and protein assays) have been developed to provide noninvasive adjunctive testing. Biomarker performance varies by tumor grade and stage: many tests show higher sensitivity but lower specificity compared with cytology, and sensitivity generally improves with higher grade/stage disease. Evidence and guideline statements note that urinary biomarkers can increase sensitivity when used with cytology but have produced false positives and missed cancers in some studies, and therefore should not replace cystoscopy in routine practice; biomarkers may be considered as adjuncts in surveillance of high‑risk NMIBC or to adjudicate equivocal cytology.

Study / Source	Key findings
Chou et al. meta-analysis (57 studies)
Sensitivities 0.57-0.82; specificities 0.74-0.88; many false positives and missed cancers

Operational thresholds

BTA manufacturer cut‑off14 U/mL (manufacturer‑recommended)

NMP22 FDA‑approved cut‑off10 U/mL (FDA‑approved)

Bladder CARE sample requirementAs little as 5 ng urine DNA from a 100 mL urine sample; limit of detection 0.1%

Definitions / Terminology

Term	Definition
BTA
Bladder tumor antigen
NMP22
Nuclear matrix protein 22
FISH / UroVysion
Fluorescence in situ hybridization assay detecting chromosomal alterations
ImmunoCyt / uCyt+
Fluorescence immunocytology assay to detect glycoproteins expressed on cancerous cells (surveillance adjunct)
LDT
Laboratory-developed test (regulated under CLIA '88; not FDA-approved)
UroVysion
A FISH-based urine assay detecting aneuploidy of chromosomes 3,7,17 and 9p21 locus loss for detection of bladder cancer in patients with hematuria.
ImmunoCyt
A qualitative direct immunofluorescence assay used with cytology to increase sensitivity for detecting tumor cells in urine; indicated for surveillance.

Revision History

Policy Summary

Payerblue cross blue shield - tennessee

PolicyUrinary Tumor Markers for Bladder Cancer - G2125

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

SourceLink

On This Page

Urinary biomarkers (BTA, NMP22, UroVysion FISH) DO NOT MEET COVERAGE CRITERIA for screening of bladder cancer
Urinary biomarkers (BTA, NMP22, UroVysion FISH) DO NOT MEET COVERAGE CRITERIA for evaluation of hematuria
Urinary biomarkers (BTA, NMP22, UroVysion FISH) DO NOT MEET COVERAGE CRITERIA for diagnosing bladder cancer in symptomatic individuals
Urinary biomarkers (BTA, NMP22, UroVysion FISH) DO NOT MEET COVERAGE CRITERIA for all other indications
Fluorescence immunocytology (ImmunoCyt/uCyt) DOES NOT MEET COVERAGE CRITERIA in the evaluation of hematuria
Fluorescence immunocytology (ImmunoCyt/uCyt) DOES NOT MEET COVERAGE CRITERIA for diagnosing bladder cancer
Fluorescence immunocytology (ImmunoCyt/uCyt) DOES NOT MEET COVERAGE CRITERIA for screening for bladder cancer in asymptomatic persons
Any other urinary tumor markers for bladder cancer not mentioned above DO NOT MEET COVERAGE CRITERIA

Regulatory and Indication Statements

Statements about FDA approvals and authorized indications:

UroVysion Bladder Cancer Kit is FDA approved to detect aneuploidy for chromosomes 3, 7, 17 and loss of the 9p21 locus via FISH in urine specimens from persons with hematuria suspected of having bladder cancer.

ImmunoCyt was FDA approved (February 23, 2000) as a qualitative direct immunofluorescence assay intended for use in conjunction with cytology to increase overall sensitivity for detection of tumor cells exfoliated in urine of patients previously diagnosed with bladder cancer; indicated for use as an aid in management of bladder cancer in conjunction with urinary cytology and cystoscopy.

ImmunoCyt is surveillance-only (FDA indication).

All FDA-approved tests apart from ImmunoCyt are approved for both diagnosis and surveillance of bladder cancer whereas ImmunoCyt is only approved for surveillance.

Laboratory-Developed Tests (LDTs) Regulatory Status

Many laboratories have developed specific tests that they validate and perform in-house as laboratory-developed tests (LDTs).

LDTs are regulated by CMS as high-complexity tests under CLIA '88 and are not approved or cleared by the FDA; FDA clearance or approval is not currently required for clinical use.

Documentation Required

ImmunoCyt/uCyt surveillance limitation

ImmunoCyt (uCyt+) is FDA‑approved and covered only as an adjunct in surveillance of patients previously diagnosed with bladder cancer; use outside this surveillance context (for diagnosis, hematuria evaluation, or screening) may be noncovered.

Billing Rule

Laboratory-developed tests (LDTs)

Laboratory‑developed tests (LDTs) are regulated by CMS under CLIA '88 as high‑complexity tests and are not FDA‑approved; LDTs may be used clinically but require local validation and coverage may depend on the member's benefit.

Document local validation of the LDT
Maintain CLIA '88 high‑complexity compliance documentation
Confirm coverage determination per the patient's benefit/plan

Documentation Required

Use of ImmunoCyt

ImmunoCyt should be ordered and documented only in conjunction with urinary cytology and cystoscopy for surveillance of patients previously diagnosed with bladder cancer; document the clinical history supporting surveillance use.

Documentation Required

Use of UroVysion

UroVysion is intended for urine specimens from persons with hematuria suspected of having bladder cancer; when ordering, document presence of hematuria and the clinical suspicion for bladder cancer.

Documentation Required

Laboratory LDT validation

Labs performing LDTs must validate their tests and keep validation records and other documentation demonstrating compliance with CLIA '88 high‑complexity testing requirements.

Maintain formal validation records for the LDT
Retain CLIA '88 high‑complexity compliance documentation
Be prepared for coverage review per member benefits